Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 3Breast 3Thoracic 2Gynecologic 2Head & Neck 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Neoplasms 11Neoplasm Metastasis 3

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × niraparib × Tumor-Agnostic × Clear all
NCT04170153 2026-05-07

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

EMD Serono

Phase 1 Active not recruiting
161 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04817956 2024-02-29

IMPRESS-N

Oslo University Hospital

Phase 2 Recruiting
3,000 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡